Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BerGenBio ASA (BRRGF)
OTHER OTC:BRRGF
Holding BRRGF?
Track your performance easily
BRRGF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.03 - $0.03
Previous Close$0.03
Volume37.30K
Average Volume (3M)37.30K
Market Cap
$29.36M
Enterprise Value$437.19M
Total Cash (Recent Filing)kr0.00
Total Debt (Recent Filing)kr407.83M
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Feb 19, 2025EPS Estimate
-$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding88,660,532
10 Day Avg. Volume0
30 Day Avg. Volume37,305
Standard Deviation0.63
R-Squared0.00457
Alpha0.00951
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)1.34
Price to Sales (P/S)243.19
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.34Price Target Upside33.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
BerGenBio ASA News
PremiumCompany Announcements
BerGenBio Highlights Clinical Progress and Strategy
PremiumCompany Announcements
BerGenBio ASA Appoints New CEO to Lead Growth
PremiumCompany Announcements
BerGenBio Reports Q3 2024 Earnings and Strategy Updates
PremiumCompany Announcements
BerGenBio Reports Progress in Cancer Drug Development
PremiumPre-Earnings
Is BRRGF a Buy, Before Earnings?
PremiumCompany Announcements
BerGenBio ASA CEO Martin Olin Steps DownPremiumCompany Announcements
BerGenBio ASA’s Extraordinary Meeting Concludes Successfully
PremiumCompany Announcements
BerGenBio’s Bemcentinib Shows Promise in Lung Cancer StudyBulls Say, Bears Say
Bulls Say
Market OpportunityBerGenBio has an opportunity to capture market share by targeting the STK11 mutation in lung cancer patients, where the unmet medical need is significant.
Regulatory And Clinical ProgressThis development follows the green light from the independent drug safety monitoring board (DSMB) to proceed without alterations, confirming the safety of bemcentinib in combination with pembro and doublet chemotherapy observed in the Phase 1b segment.
Safety And EfficacyBerGenBio announced preliminary safety and pharmacokinetic data for bemcentinib with no unexpected safety signals observed.
Bears Say
Drug DevelopmentPatients with STK11 mutations often have resistance to immune checkpoint inhibitors and are associated with a worse prognosis compared to STK11-negative patients.
Partnership And CollaborationInability to secure an attractive partnership on favorable terms led to the discontinuation of internal development of tilvestamab.
Product SafetyThe therapeutic window for ADCT-601 is too narrow, likely due to toxicities, impacting its development.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
― Other Institutional Investors
100.00% Public Companies and
Individual Investors
BRRGF FAQ
What was BerGenBio ASA’s price range in the past 12 months?
BerGenBio ASA lowest stock price was $0.03 and its highest was $0.03 in the past 12 months.
What is BerGenBio ASA’s market cap?
Currently, no data Available
When is BerGenBio ASA’s upcoming earnings report date?
BerGenBio ASA’s upcoming earnings report date is Feb 19, 2025 which is in 52 days.
How were BerGenBio ASA’s earnings last quarter?
BerGenBio ASA released its earnings results on Nov 13, 2024. The company reported -$0.055 earnings per share for the quarter, beating the consensus estimate of -$0.118 by $0.062.
Is BerGenBio ASA overvalued?
According to Wall Street analysts BerGenBio ASA’s price is currently Undervalued.
Does BerGenBio ASA pay dividends?
BerGenBio ASA does not currently pay dividends.
What is BerGenBio ASA’s EPS estimate?
BerGenBio ASA’s EPS estimate is -$0.1.
How many shares outstanding does BerGenBio ASA have?
BerGenBio ASA has 39,087,116 shares outstanding.
What happened to BerGenBio ASA’s price movement after its last earnings report?
BerGenBio ASA reported an EPS of -$0.055 in its last earnings report, beating expectations of -$0.118. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BerGenBio ASA?
Currently, no hedge funds are holding shares in BRRGF
---
Company Description
BerGenBio ASA
BerGenBio ASA is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers.
---
BRRGF Company Deck
---
BRRGF Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment, with positive developments in the BGB16 study and financial management, but faced setbacks with program discontinuations and the CEO's upcoming departure.Read More>---
BRRGF Stock 12 Month Forecast
Average Price Target
$3.34
▲(33.60% Upside)
Technical Analysis
Best Analysts Covering BRRGF
1 Year
1 Year Success Rate
0/11 ratings generated profit
1 Year Average Return
-19.04%
reiterated a buy rating 7 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -19.04% per trade.
---